中医二联疗法治疗隐匿性肾小球肾炎120例回顾性分析
发布时间：2018-01-27 09:19
本文关键词： 二联疗法 穴位贴敷 固本培元方 隐匿性肾小球肾炎 血尿 蛋白尿 出处：《辽宁中医药大学》2016年硕士论文 论文类型：学位论文
【摘要】：目的:回顾性分析隐匿性肾小球肾炎患者的蛋白尿和血尿变化,以探讨二联疗法(培本固元方+穴位贴敷)的临床疗效。方法:通过电子病历系统,收集符合纳入标准的患者,通过分组标准以及时间顺序在观察组以及对照组各纳入60例患者,共120例。120例患者均予基础内科治疗以及培本固元方治疗,观察组在这个方案基础上增加穴位贴敷治疗,120例患者均治疗2周,分析治疗前后患者的中医症候积分尿沉渣RBC计数尿蛋白等相关指标的变化。通过回顾性分析治疗前后肝功能肾功能血常规尿常规便常规心电图等指标的变化,以评价二联疗法的安全性。结果:1.干预治疗后,观察组疾病疗效总有效率75.0%,对照组疾病疗效总有效率72.7%,差异无统计学意义(P0.05)。2.干预治疗后,二联疗法中医证侯疗效总有效率96.7%,对照组中医证侯疗效总有效率86.7%,差异有显著统计学意义(P0.01)。3.干预治疗后两组证侯总积分均优于治疗前,差异有显著统计学意义(P0.01);两组间比较差异具有显著统计学意义(P0.01)。4.干预治疗后两组尿沉渣RBC计数均较治疗前有显著改善,差异具有显著统计学意义(P0.01);观察组尿沉渣RBC计数较非二联疗法差别较小,差异无统计学意义(P0.05)。5.干预治疗后观察组尿蛋白定量与治疗前比较,差异具有显著统计学意义(P0.01);非二联疗法尿蛋白与治疗前比较,差异有显著统计学意义(P0.01);治疗后两组间尿蛋白比较,差异无统计学意义(P0.05)。6.观察组患者在应用二联疗法后均未出现明显不适症状,治疗前后肝功能肾功能血常规尿常规便常规心电图比较,差异无统计学意义(P0.05)。结论:二联疗法能显著改善患者临床症状和体征,降低尿沉渣RBC计数尿蛋白水平,具有良好的临床疗效,疗法安全可靠。
[Abstract]:Objective: to retrospectively analyze the changes of proteinuria and hematuria in patients with occult glomerulonephritis, and to explore the clinical effect of combined therapy. The patients who met the inclusion criteria were collected, and 60 patients were included in the observation group and the control group respectively by grouping criteria and time order. 120 cases (120 cases) were treated with basic medical treatment and Peibengu Yuan prescription, and 120 patients in observation group were treated for 2 weeks. Analysis of patients before and after treatment of TCM symptom score? Urine sediment RBC count? Changes in urinary protein and other related indicators. By retrospective analysis of liver function before and after treatment? Kidney function? Blood routine? Urine routine? Convention? Changes of electrocardiogram and other indicators to evaluate the safety of combined therapy. Results: 1. After intervention, the total effective rate of disease in the observation group was 75.0 and that in the control group was 72.7%. After the intervention treatment, the total effective rate of TCM syndromes was 96.77.The total effective rate of TCM syndromes in the control group was 86.7%. After intervention treatment, the total score of the two groups was better than that before treatment, and the difference was statistically significant (P 0.01). The difference between the two groups was statistically significant (P 0.01). After the intervention treatment, the RBC count of urinary sediment in the two groups was significantly improved compared with that before treatment. The difference was statistically significant (P 0.01). The RBC count of urine sediment in the observation group was smaller than that in the non-dual therapy group, and the difference was not statistically significant (P0.050.5.After the intervention treatment, the urine protein quantity in the observation group was compared with that before treatment. The difference was statistically significant (P 0.01). There was a significant difference in urine protein between non-diadectic therapy and pre-treatment (P 0.01). There was no significant difference in urine protein between the two groups after treatment. The patients in the observation group had no obvious symptoms after the application of combined therapy and the liver function before and after treatment. Kidney function? Blood routine? Urine routine? Convention? There was no significant difference in electrocardiogram (ECG). Conclusion: dual therapy can significantly improve the clinical symptoms and signs of patients and reduce the RBC count of urinary sediment. Urine protein level, has good clinical effect, the treatment is safe and reliable.
【学位授予单位】：辽宁中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R277.5
，
本文编号：1468127
本文链接：https://www.wllwen.com/zhongyixuelunwen/1468127.html
最近更新
教材专著
